We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Potential Noninvasive Biomarker of EoE Disease Activity Identified

By LabMedica International staff writers
Posted on 24 May 2016
Image: A micrograph of eosinophilic esophagitis (EoE), H&E stain. Characteristic features are present: Abundant eosinophils – criteria vary; one common definition is: > 20 eosinophils/0.24 mm2; Papillae are elongated; papillae reach into the top 1/3 of the epithelial layer; Basal cell hyperplasia; > 3 cells thick or >15% of epithelial thickness; Spongiosis (Photo courtesy of Michael Bonert / Wikimedia).
Image: A micrograph of eosinophilic esophagitis (EoE), H&E stain. Characteristic features are present: Abundant eosinophils – criteria vary; one common definition is: > 20 eosinophils/0.24 mm2; Papillae are elongated; papillae reach into the top 1/3 of the epithelial layer; Basal cell hyperplasia; > 3 cells thick or >15% of epithelial thickness; Spongiosis (Photo courtesy of Michael Bonert / Wikimedia).
Researchers have identified a potential blood-based marker of disease activity for the severe and often painful food allergic disease eosinophilic esophagitis (EoE) – possibly leading to a blood test, which could spare EoE patients, often children, the discomfort and risk of the currently used invasive endoscopic monitoring procedures.

Researchers at the Cincinnati Center for Eosinophilic Disorders (CCED) of Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) led the study. “Adults and children with EoE can be on highly restricted diets of formula alone or only a few foods,” said Patricia C. Fulkerson, MD, PhD, senior study author, “One of the major obstacles to families participating in studies to introduce foods back into the child’s diet is the need for endoscopy after each food is tried to see whether or not it triggers disease activity.”

The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires endoscopy to collect esophageal tissue biopsies. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, require additional endoscopic exams to assess for disease flare-ups.

Prior research has demonstrated that testing blood of EoE patients is not a clinically useful indication of active disease because eosinophil levels in blood do not correlate well with levels in the esophagus. This led the team to investigate a precursor cell to eosinophils, a lineage-committed eosinophil progenitor (EoP), as a potential marker. They found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker.

The authors emphasize that additional research is needed to validate the marker before routine clinical use. “This clinical study is the first to investigate EoP levels in patients with EoE and identifies a potential new noninvasive biomarker,” said study author Vincent A. Mukkada, MD, physician at Cincinnati Children’s and CCED member, “This work is an essential step toward improving outcomes for patients with EoE. It will be followed by repeated testing of more patients and with sequential measurements of EoP levels in the same patient during different disease states.”

Allergic diseases have been on the rise over the past 20 years. The CCED team has previously reported that incidence of EoE is estimated at 1 of 1,000 people. Their research has also shown that EoE is caused by a combination of genetic and environmental factors, and is primarily mediated by an immunologic response to foods. The hallmark of EoE is swelling and inflammation in the esophagus, accompanied by high levels of eosinophils.

The study, by Morris DW et al, was published May 16, 2016, in the Journal of Allergy and Clinical Immunology.

Related Links:
Cincinnati Children’s Hospital Medical Center

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL